Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

An Introduction to CPHI Milan 2026

ByTara Dougal,Susan Haigney

September 3rd 2026

Autonomous solubility tester. Imitation dissolution of the tablet in the human stomach. Scientific research of pharmaceutical laboratory. Laboratory research in pharmacy. | Image Credit: ©neznamov1984 -stock.adobe.com

Application of Predictive Modeling in the Development of Amorphous Solid Dispersions

ByCynthia A. Challener

September 3rd 2026

Novartis and Bristol-Myers Squibb pause CAR T-cell trials after 3 releated deaths.

CAR T-Cell Trial Pause Signals New Manufacturing Risk Review

ByZachary Zubulake

September 2nd 2026

AAPS PharmSci 360: CMC Strategies, Part 1

ByAlfred Rumondor, PhD,Swita Singh, PhD,Susan Haigney

September 2nd 2026

Novartis makes a $3.2 Billion bet on a subcutaneous formulation platform.

What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation

ByZachary Zubulake

September 2nd 2026

USP's Semi-Hemiquinquennial Meeting

Articles in this issue

Related Content

An Introduction to CPHI Milan 2026

Application of Predictive Modeling in the Development of Amorphous Solid Dispersions

CAR T-Cell Trial Pause Signals New Manufacturing Risk Review

AAPS PharmSci 360: CMC Strategies, Part 1

What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation

Trending on Pharmaceutical Technology

What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation

CAR T-Cell Trial Pause Signals New Manufacturing Risk Review

AAPS PharmSci 360: CMC Strategies, Part 1

CPHI Milan Names 2026 Pharma Awards Finalists

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 1